




RealRate

# PHARMACEUTICAL 2013

Panbela Therapeutics Inc  
Rank 139 of 218



The relative strengths and weaknesses of Panbela Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Panbela Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Panbela Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 174% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 55% points below the market average of 220%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 337                  |
| Cost of Goods Sold                          | 692                  |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 644                  |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 258                  |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 149                  |
| Other Liabilities                           | 8.2                  |
| Other Net Income                            | 1.0                  |
| Other Revenues                              | 1,233                |
| Property and Equipment                      | 16                   |
| Research and Development                    | 0                    |
| Selling, General and Administrative Expense | 145                  |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 611                  |
| Liabilities                 | 652                  |
| Expenses                    | 986                  |
| Revenues                    | 1,233                |
| Stockholders Equity         | -41                  |
| Net Income                  | 247                  |
| Comprehensive Net Income    | 247                  |
| BaseVar                     | 1,741                |
| ECR before LimitedLiability | 25%                  |
| Economic Capital Ratio      | 165%                 |